Cargando…

Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy

Neoadjuvant platin-based therapy is accepted as a standard therapy for advanced esophageal adenocarcinoma (EAC). Patients who respond have a better survival prognosis, but still a significant number of responder patients die from tumor recurrence. Molecular markers for prognosis in neoadjuvantly tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aichler, Michaela, Motschmann, Martin, Jütting, Uta, Luber, Birgit, Becker, Karen, Ott, Katja, Lordick, Florian, Langer, Rupert, Feith, Marcus, Siewert, Jörg Rüdiger, Walch, Axel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196151/ https://www.ncbi.nlm.nih.gov/pubmed/25216514

Ejemplares similares

High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma
por: Rauser, Sandra, et al.
Publicado: (2010)

Native glycan fragments detected by MALDI-FT-ICR mass spectrometry imaging impact gastric cancer biology and patient outcome
por: Kunzke, Thomas, et al.
Publicado: (2017)

Expression and clinical significance of Glucose Regulated Proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus
por: Langer, Rupert, et al.
Publicado: (2008)

Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas
por: Schmidt, T, et al.
Publicado: (2014)

A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients
por: Blank, Susanne, et al.
Publicado: (2014)

Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus
por: Slotta-Huspenina, Julia, et al.
Publicado: (2014)

De novo discovery of metabolic heterogeneity with immunophenotype-guided imaging mass spectrometry
por: Prade, Verena M., et al.
Publicado: (2020)

MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus
por: Slotta-Huspenina, Julia, et al.
Publicado: (2018)

The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma
por: Richter, Igor, et al.
Publicado: (2015)

A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomas
por: Adams, Olivia, et al.
Publicado: (2018)

Correction to: MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus
por: Slotta-Huspenina, Julia, et al.
Publicado: (2018)

Correction: A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomas
por: Adams, Olivia, et al.
Publicado: (2019)

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas
por: Magkou, Christina, et al.
Publicado: (2008)

Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2017)

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Luber, Birgit, et al.
Publicado: (2011)

Epidermal growth factor receptors (EGFR) in human ovarian cancer.
por: Owens, O. J., et al.
Publicado: (1991)

Development of an Epidermal Growth Factor Derivative with EGFR Blocking Activity
por: Panosa, Clara, et al.
Publicado: (2013)

Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer
por: Berasain, Carmen, et al.
Publicado: (2011)

Nuclear localization of epidermal growth factor receptor (EGFR) in ameloblastomas
por: Pereira, Núbia Braga, et al.
Publicado: (2015)

Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma
por: Wernicke, A Gabriella, et al.
Publicado: (2010)

Targeting Epidermal Growth Factor Receptor (EGFR) in Pediatric Colorectal Cancer
por: De Pasquale, Maria Debora, et al.
Publicado: (2020)

Association of epidermal growth factor receptor (EGFR) gene polymorphisms with endometriosis
por: Wang, Yu-Mei, et al.
Publicado: (2019)

AXL/epidermal growth factor receptor (EGFR) complexes in breast cancer - culprits for resistance to EGFR inhibitors?
por: Heideman, Marinus R, et al.
Publicado: (2013)

ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)
por: Hoeppner, Jens, et al.
Publicado: (2016)

Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Lung Adenocarcinoma
por: Makinoshima, Hideki, et al.
Publicado: (2014)

Hypermethylated Epidermal growth factor receptor (EGFR) promoter is associated with gastric cancer
por: Weng, Xiaoling, et al.
Publicado: (2015)

Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment
por: Sasada, Tetsuro, et al.
Publicado: (2016)

Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial
por: Lorenzen, S, et al.
Publicado: (2008)

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)
por: Kaufman, Nichole E. M., et al.
Publicado: (2021)

Tumor Regression Grading of Gastrointestinal Carcinomas after Neoadjuvant Treatment
por: Thies, Svenja, et al.
Publicado: (2013)

A specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas
por: Slotta-Huspenina, J, et al.
Publicado: (2013)

Chances, risks and limitations of neoadjuvant therapy in surgical oncology
por: Lordick, Florian, et al.
Publicado: (2016)

Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis
por: Keller, Simone, et al.
Publicado: (2017)

Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
por: Jorge, S.E.D.C., et al.
Publicado: (2014)

Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage
por: Rayego-Mateos, Sandra, et al.
Publicado: (2018)

Toward structure-based drug design against the epidermal growth factor receptor (EGFR)
por: Haddad, Yazan, et al.
Publicado: (2020)

Prognostic Worth of Epidermal Growth Factor Receptor (EGFR) in Patients with Head and Neck Tumors
por: Barnes, Precious, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
por: Peraldo-Neia, Caterina, et al.
Publicado: (2011)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
por: Park, Ha Young, et al.
Publicado: (2016)

Epidermal Growth Factor Receptor Inhibition with Erlotinib Partially Prevents Cisplatin-Induced Nephrotoxicity in Rats
por: Wada, Yukihiro, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fhmrdkrnl441e9s94slga9m3o9